Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Is Adapting To New Pricing Reality, Says GSK Chief Andrew Witty

This article was originally published in The Pink Sheet Daily

Executive Summary

Andrew Witty shines a positive light on value-based pricing and adds his voice to calls for harmonized HTAs across Europe.

You may also be interested in...

EFPIA Calls On Drug Firms To Embrace Multi HTA Early Dialogue Scheme

EFPIA is calling on its members to sign up to the European Commission’s multi HTA early dialogue initiative to harmonize some significant aspects of European reimbursement.

German Reimbursement Dossiers Look Trickier After Rejection Of Eisai’s Fycompa

Eisai’s novel epilepsy drug Fycompa will have a tough time qualifying for reimbursement in Germany after the cost-effectiveness regulator IQWiG said the manufacturer did not stick to HTA guidance on comparator selection.

GSK To Downplay Europe Because of Poor Innovation Support, Focuses On Japan, U.S. Instead

GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts